Related Experiment Video
Updated: Feb 22, 2026
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers
Elizabeth L Siegler1, Yu Jeong Kim2, Xianhui Chen2
1Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Abstract:
The therapeutic limitations of conventional chemotherapeutic drugs include chemo-resistance, tumor recurrence, and metastasis. Numerous nanoparticle-based active targeting approaches have emerged to enhance the intracellular concentration of drugs in tumor cells; however, efficient delivery of these systems to the tumor site while sparing healthy tissue remains elusive. Recently, much attention has been given to human immune-cell-directed nanoparticle drug delivery, because immune cells can traffic to the tumor and inflammatory sites. Natural killer cells are a subset of cytotoxic lymphocytes that play critical roles in cancer immunosurveillance. Engineering of the human natural killer cell line, NK92, to express chimeric antigen receptors to redirect their antitumor specificity has shown significant promise. We demonstrate that the efficacy of chemotherapy can be enhanced in vitro and in vivo while reducing off-target toxicity by using chimeric antigen receptor-engineered NK92 cells as carriers to direct drug-loaded nanoparticles to the target site.
Insights
Engineered natural killer (NK) cells carrying drug-loaded nanoparticles show promise for cancer therapy. This approach enhances chemotherapy effectiveness in vitro and in vivo while minimizing side effects on healthy tissues.
Area of Science:
- Oncology
- Immunotherapy
- Nanomedicine
Background:
- Conventional chemotherapy faces limitations like drug resistance and metastasis.
- Nanoparticle drug delivery aims to improve tumor cell drug concentration but struggles with targeting and off-tumor toxicity.
- Immune cells offer a promising avenue for targeted nanoparticle delivery due to their natural trafficking to tumor sites.
Purpose of the Study:
- To investigate the potential of chimeric antigen receptor-engineered NK92 cells as carriers for targeted drug delivery.
- To evaluate the efficacy and safety of this approach in enhancing chemotherapy against cancer.
Main Methods:
- Engineering NK92 natural killer cells with chimeric antigen receptors to target cancer cells.
- Loading nanoparticles with chemotherapeutic drugs.
- Utilizing engineered NK92 cells to deliver drug-loaded nanoparticles to tumor sites.
- Assessing therapeutic efficacy and off-target toxicity in vitro and in vivo.
Main Results:
- Chimeric antigen receptor-engineered NK92 cells successfully delivered drug-loaded nanoparticles to target sites.
- Enhanced chemotherapy efficacy was observed in vitro and in vivo.
- Reduced off-target toxicity was noted compared to conventional delivery methods.
Conclusions:
- Chimeric antigen receptor-engineered NK92 cells represent a viable strategy for targeted nanoparticle drug delivery in cancer therapy.
- This approach holds potential for improving chemotherapy outcomes by increasing efficacy and reducing systemic toxicity.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...